1 | 20 mg/ml Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
2 | Abatacept Active Treatment | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 50 50 |
3 | Abatacept Delayed-Onset Treatment | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 50 50 |
4 | Active Investigational Treatment ENT-01 | - | - | - | - | 1件: 6 6 |
5 | Active Treatment Group 7% Hypertonic Saline | - | - | - | - | 1件: 299 299 |
6 | Aesculus Hippocastanum / Horse Chestnut (Synonym: Conker tree) | 1件: Horse chestnut Horse chestnut | 1件: D12028
D12028
(Name: Conker tree) | - | - | 1件: 210 210 |
7 | All patients in the study will be treated with ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
8 | Baclofen (baclofen Tab. 10mg) treatment | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 70 70 |
9 | Baricitinib treatment | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
10 | Baseline Treatment | - | - | - | - | 1件: 13 13 |
11 | BDMARD treatment | - | - | - | - | 1件: 271 271 |
12 | Bendamustine (Synonym: Treanda (TN)) | 1件: Bendamustine Bendamustine (Synonym: Treanda) | 1件: D07501
D07501
(Name: Treanda (TN)) | - | - | 2件: 28 28, 61 |
13 | BENDAMUSTINE HYDROCHLORIDE (Synonym: Treanda (TN)) | 1件: Bendamustine Bendamustine (Synonym: Treanda) | 1件: D07501
D07501
(Name: Treanda (TN)) | - | - | 1件: 61 61 |
14 | Bendamustine, Rituximab (Synonym: Treanda (TN)) | 2件: Bendamustine Bendamustine (Synonym: Treanda), Rituximab | 2件: D02994
D02994
,
D07501
(Name: Treanda (TN)) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 61 61 |
15 | Best Medical Treatment | - | - | - | - | 1件: 6 6 |
16 | Best médical treatment | - | - | - | - | 1件: 6 6 |
17 | Bisphosphonate treatment | - | - | - | - | 2件: 113 113, 299 |
18 | Botulism Toxin Treatment | - | - | - | - | 1件: 161 161 |
19 | Break in L-carnitine treatment | 1件: Levocarnitine Levocarnitine | 1件: D02176
D02176
| - | - | 1件: 316 316 |
20 | C-Trelin OD Tab(5mg Taltirelin Hydrate) | - | - | - | - | 1件: 18 18 |
21 | Carbidopa/levodopa, as prescribed by treating physician | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
22 | CF patients with a G551D mutation and treated with Ivacaftor | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
23 | Chinese herbal medicine treatment | - | - | - | - | 1件: 6 6 |
24 | Classic DMARDs treatment group | - | - | - | - | 1件: 46 46 |
25 | Clobetasol Propionate cream treatment | 2件: Clobetasol Clobetasol, Clobetasol propionate | 2件: D01272
D01272
,
D07715
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
26 | Clopidogrel treatment | 1件: Clopidogrel Clopidogrel | 3件: D07729
D07729
,
D10823
,
D10824
| 1件: P2RY12 P2RY12 💬 | 1件: Platelet activation Platelet activation 💬 | 1件: 51 51 |
27 | Combination Product: Active treatment with dual therapy | - | - | - | - | 1件: 2 2 |
28 | Combination Product: Implantable System for Remodulin (treprostinil) | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
29 | Combination Product: Treprostinil via implanted pump | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
30 | Conventional treatment | - | - | - | - | 1件: 97 97 |
31 | Conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine) | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 2件: 96 96, 97 |
32 | Corticosteroid treatment (Methylprednisolone or prednisolone) | 2件: Methylprednisolone Methylprednisolone, Prednisolone | 2件: D00407
D00407
,
D00472
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 64 64 |
33 | Crysvita (burosumab-twza) Treatment | 1件: Burosumab Burosumab | 1件: D10913
D10913
| 1件: FGF23 FGF23 💬 | 11件: Breast cancer Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬 | 1件: 238 238 |
34 | Current lipid-lowering treatment | - | - | - | - | 1件: 79 79 |
35 | Current treatment of AL-CM | - | - | - | - | 1件: 28 28 |
36 | Cutaneous iontophoresis of treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 |
37 | Cytokine-treated Veto Cells | - | - | - | - | 1件: 60 60 |
38 | Deferiprone treated | 1件: Deferiprone Deferiprone | 1件: D07416
D07416
| - | - | 1件: 120 120 |
39 | Detoxifying agents for antineoplastic treatment | - | - | - | - | 2件: 299 299, 337 |
40 | Dietanolamina de treprostinilo | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
41 | Disease modifying treatment (DMT) | - | - | - | - | 1件: 13 13 |
42 | Disease modifying treatments | - | - | - | - | 1件: 3 3 |
43 | Dopamine agonist treatment | 1件: Dopamine Dopamine | 1件: D07870
D07870
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 74 74 |
44 | Drug treatment | - | - | - | - | 3件: 51 51, 74, 271 |
45 | ERA as specific PAH treatment | - | - | - | - | 1件: 86 86 |
46 | Etanercept Treatment | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
47 | Eutonic Treprostinil Solution | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
48 | Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab) | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 |
49 | Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS | - | - | - | - | 1件: 13 13 |
50 | Fibrate treatment | - | - | - | - | 1件: 160 160 |
51 | Foliglurax 10 mg (treatment A) | 1件: Foliglurax Foliglurax | - | - | - | 1件: 6 6 |
52 | Foliglurax 30 mg (treatment B) | 1件: Foliglurax Foliglurax | - | - | - | 1件: 6 6 |
53 | Follow-up study of the treated cohort | - | - | - | - | 1件: 193 193 |
54 | From August 2020 'no additional treatment' | - | - | - | - | 1件: 51 51 |
55 | Gabapentin (neurontin® capsule 300mg) treatment | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 70 70 |
56 | GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made. | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 |
57 | Glucocorticoid Treatment | - | - | - | - | 1件: 41 41 |
58 | Golimumab treatment optimization. | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
59 | Group 1 or Orencia treated group | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
60 | GUSELKUMAB (Synonym: Tremfya (TN)) | 1件: Guselkumab Guselkumab (Synonym: Tremfya) | 1件: D10438
D10438
(Name: Tremfya (TN)) | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 5件: 37 37, 41, 51, 96, 97 |
61 | Guselkumab 100 mg (Synonym: Tremfya (TN)) | 1件: Guselkumab Guselkumab (Synonym: Tremfya) | 1件: D10438
D10438
(Name: Tremfya (TN)) | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 37 37 |
62 | Guselkumab Dose 1 (Synonym: Tremfya (TN)) | 1件: Guselkumab Guselkumab (Synonym: Tremfya) | 1件: D10438
D10438
(Name: Tremfya (TN)) | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 3件: 51 51, 96, 97 |
63 | Guselkumab Dose 2 (Synonym: Tremfya (TN)) | 1件: Guselkumab Guselkumab (Synonym: Tremfya) | 1件: D10438
D10438
(Name: Tremfya (TN)) | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 3件: 51 51, 96, 97 |
64 | Guselkumab Dose 3 (Synonym: Tremfya (TN)) | 1件: Guselkumab Guselkumab (Synonym: Tremfya) | 1件: D10438
D10438
(Name: Tremfya (TN)) | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 96 96, 97 |
65 | Guselkumab Dose 4 (Synonym: Tremfya (TN)) | 1件: Guselkumab Guselkumab (Synonym: Tremfya) | 1件: D10438
D10438
(Name: Tremfya (TN)) | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 |
66 | Guselkumab Dose 5 (Synonym: Tremfya (TN)) | 1件: Guselkumab Guselkumab (Synonym: Tremfya) | 1件: D10438
D10438
(Name: Tremfya (TN)) | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 |
67 | HAESCs treatment | - | - | - | - | 1件: 6 6 |
68 | HCQ/CQ and CAB combined treatment | - | - | - | - | 1件: 74 74 |
69 | Herbal treatment (SA100) | - | - | - | - | 1件: 97 97 |
70 | Horse chestnut (Synonym: Conker tree) | 1件: Horse chestnut Horse chestnut | 1件: D12028
D12028
(Name: Conker tree) | - | - | 1件: 210 210 |
71 | Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment | 1件: Xenon Xenon | 2件: D01901
D01901
,
D06339
| - | - | 1件: 85 85 |
72 | Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment | 1件: Xenon Xenon | 2件: D01901
D01901
,
D06339
| - | - | 1件: 85 85 |
73 | Immunosuppressive treatment | - | - | - | - | 1件: 66 66 |
74 | Immunosuppressive treatment (eg, rituximab) | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 64 64 |
75 | In double-blind phase: treatment with tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 107 107 |
76 | In open-label phase: treatment with tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 107 107 |
77 | Inhaled dry powder treprostinil (LIQ861) | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
78 | Inhaled Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 3件: 84 84, 85, 86 |
79 | Interferon beta treatment to add-on atorvastatin treatment | 2件: Atorvastatin Atorvastatin, Human interferon beta | 1件: D07474
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
80 | Intravenous Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
81 | Iontophoresis of treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 |
82 | IV treatment with IGSC, 10% | - | - | - | - | 1件: 65 65 |
83 | L606 (Liposomal Treprostinil) Inhalation Solution 51ug | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
84 | Lapaquistat acetate and current lipid-lowering treatment | 2件: Acetate Acetate, Lapaquistat | - | - | - | 1件: 79 79 |
85 | Large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP | 5件: Dapsone Dapsone, Mycophenolate mofetil, Mycophenolic acid, Prednisolone, Triamcinolone (Synonym: Treziopak) | 5件: D00385
D00385
,
D00472
,
D00592
,
D00752
,
D05096
| 3件: IMPDH1 IMPDH1, IMPDH2, NR3C1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬 | 1件: 162 162 |
86 | LIQ861 Inhaled Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
87 | Lumacaftor-Ivacaftor treatment | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: D09916
D09916
,
D10134
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
88 | Metformin treatment | 1件: Metformin Metformin | 1件: D04966
D04966
| 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 46 46 |
89 | Methotrexate treatment | 1件: Methotrexate Methotrexate (Synonym: Trexall) | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 2件: 41 41, 46 |
90 | MK0812 / Duration of Treatment: 12 Weeks | - | - | - | - | 1件: 46 46 |
91 | Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 |
92 | MSC treatment | - | - | - | - | 1件: 49 49 |
93 | MSC treatment 01 | - | - | - | - | 1件: 96 96 |
94 | MSC treatment 02 | - | - | - | - | 1件: 96 96 |
95 | Natalizumab treatment | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
96 | Nifurtimox-Eflronithine Combination Treatment (NECT) | 1件: Nifurtimox Nifurtimox | 1件: D00833
D00833
| - | - | 1件: 65 65 |
97 | Nusinersen Treatments | 1件: Nusinersen Nusinersen | 1件: D10881
D10881
| 1件: SMN2 SMN2 💬 | - | 1件: 3 3 |
98 | Nutrition treat | - | - | - | - | 1件: 96 96 |
99 | Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi | 4件: Epoprostenol Epoprostenol, Iloprost, Macitentan, Selexipag | 4件: D00106
D00106
,
D02721
,
D09994
,
D10135
| 3件: EDNRA EDNRA, EDNRB, PTGIR 💬 | 10件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
100 | OC oral solution treatment A | - | - | - | - | 1件: 6 6 |
101 | OC oral solution treatment B | - | - | - | - | 1件: 6 6 |
102 | OC oral solution treatment C | - | - | - | - | 1件: 6 6 |
103 | OC oral solution treatment D | - | - | - | - | 1件: 6 6 |
104 | Only 1 arm: treatment with MSC-AFP | - | - | - | - | 1件: 96 96 |
105 | Optimized antiparkinsonian treatment | - | - | - | - | 1件: 6 6 |
106 | Optimized Medical Treatment | - | - | - | - | 1件: 6 6 |
107 | Optimized oral treatment | - | - | - | - | 1件: 6 6 |
108 | Oral anticoagulant treatment | - | - | - | - | 1件: 86 86 |
109 | Oral treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 2件: 51 51, 86 |
110 | Oral treprostinil (UT-15C) Sustained Release Tablets | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
111 | Other Parkinson's Disease treatments | - | - | - | - | 1件: 6 6 |
112 | Ova-Treg | - | - | - | - | 1件: 96 96 |
113 | Ovastat 1000 (Treosulfan injection) | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
(Name: Treosulfan) | - | - | 1件: 65 65 |
114 | Ovastat 5000 (Treosulfan injection) | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
(Name: Treosulfan) | - | - | 1件: 65 65 |
115 | Parenteral Remodulin (treprostinil) injection | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
116 | Parenteral Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
117 | Patient treated with DMARD | - | - | - | - | 1件: 46 46 |
118 | Pentoxifylline (Synonym: Trental (TN)) | 1件: Pentoxifylline Pentoxifylline (Synonym: Trental Srt 400mg) | 1件: D00501
D00501
(Name: Trental (TN)) | - | - | 12件: 26 26, 56, 84, 86, 93, 96, 97, 113, 220, 222, 296, 298 |
119 | Pentoxifylline 400 MG (Synonym: Trental (TN)) | 1件: Pentoxifylline Pentoxifylline (Synonym: Trental Srt 400mg) | 1件: D00501
D00501
(Name: Trental (TN)) | - | - | 1件: 97 97 |
120 | Perfusion of treatment Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
121 | Perfusion of treatment Rituximab | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
122 | Pharmacologic approaches to glycemic treatment | - | - | - | - | 1件: 298 298 |
123 | Pioglitazone and Tretinoin | 2件: Pioglitazone Pioglitazone, Tretinoin | 2件: D00094
D00094
(Name: Tretinoin),
D08378
| 4件: PML PML, PPARG, RARA, RARB 💬 | 21件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 2 2 |
124 | Plasma from healthy young people treatment + Riluzole | 1件: Riluzole Riluzole | 1件: D00775
D00775
| 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 2 2 |
125 | Pooled Plasma (Human), Solvent/Detergent Treated | - | - | - | - | 1件: 64 64 |
126 | PPI treatment | - | - | - | - | 1件: 299 299 |
127 | Prednisone and ustekinumab treatment | 2件: Prednisone Prednisone, Ustekinumab | 2件: D00473
D00473
,
D09214
| 4件: IL12A IL12A, IL12B, IL23A, NR3C1 💬 | 29件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Neuroactive ligand-receptor interaction, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 41 41 |
128 | Prednisone treatment | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 |
129 | Propranolol treatment | 1件: Propranolol Propranolol | 1件: D08443
D08443
| 3件: ADRB1 ADRB1, ADRB2, ADRB3 💬 | 12件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 |
130 | Rapid Dose Titration Group of Subcutaneous Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
131 | Regular treatment | - | - | - | - | 1件: 97 97 |
132 | Remodulin (treprostinil sodium) | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
133 | Remodulin® (treprostinil) 1 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
134 | Remodulin® (treprostinil) 10 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
135 | Remodulin® (treprostinil) 2.5 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
136 | Remodulin® (treprostinil) 5 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
137 | Routine Treatment of CD | - | - | - | - | 1件: 96 96 |
138 | Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group) | 4件: Amitriptyline Amitriptyline, Fluoxetine, Somatotropin, Tramadol | 3件: D00326
D00326
,
D07448
,
D08623
| 3件: OPRM1 OPRM1, SLC6A2, SLC6A4 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 78 78 |
139 | SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 |
140 | SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 |
141 | Simvastatin treatment for 28 days | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 299 299 |
142 | Slow Dose Titration Group of Subcutaneous Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
143 | SLS-005 Trehalose | 1件: Trehalose Trehalose | - | - | - | 1件: 2 2 |
144 | Somatropin - GH treated cohort | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 |
145 | Standard of Care Treatment | - | - | - | - | 3件: 53 53, 245, 246 |
146 | Standard Steroid Treatment | - | - | - | - | 1件: 85 85 |
147 | Standard treatment with a conventional drug | - | - | - | - | 1件: 13 13 |
148 | Standard-of-care treatment | - | - | - | - | 1件: 49 49 |
149 | Standrd of Care treatment | - | - | - | - | 1件: 64 64 |
150 | Study treatment PPI | - | - | - | - | 1件: 166 166 |
151 | Subcutaneous Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
152 | Symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin) | 3件: Aldosterone Aldosterone, Angiotensin II, Calcium (Synonym: Restoration Treatment) | 3件: D00150
D00150
,
D02014
,
D10528
| 3件: AGTR1 AGTR1, AGTR2, NR3C2 💬 | 17件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 |
153 | Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 |
154 | Systemic non-biological treatments | - | - | - | - | 2件: 46 46, 271 |
155 | The Comprehensive Treatment Regimen of Traditional Chinese Medicine | - | - | - | - | 1件: 222 222 |
156 | The Standard Steroid Treatment, Plasma Exchange and rituximab | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 85 85 |
157 | Time delay treatment of botulinum toxin | - | - | - | - | 1件: 149 149 |
158 | TL011, anti CD20, for the treatment of rheumatoid arthritis | - | - | - | - | 1件: 46 46 |
159 | Tocilizumab treatment | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 |
160 | Top down treatment if patient at high risk | - | - | - | - | 2件: 96 96, 97 |
161 | Topical Pentoxifylline Gel (Vehicle +PTX) (Synonym: Trental (TN)) | 1件: Pentoxifylline Pentoxifylline (Synonym: Trental Srt 400mg) | 1件: D00501
D00501
(Name: Trental (TN)) | - | - | 1件: 56 56 |
162 | TR004 (Treg immunotherapy) | - | - | - | - | 1件: 96 96 |
163 | Traditional treatment of CGD and TB | - | - | - | - | 1件: 65 65 |
164 | Traditional treatments | - | - | - | - | 1件: 97 97 |
165 | TRE | - | - | - | - | 1件: 86 86 |
166 | Treat to target | - | - | - | - | 1件: 46 46 |
167 | Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms | 1件: Lansoprazole Lansoprazole (Synonym: Rugby Heartburn Treatment) | 1件: D00355
D00355
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 98 98 |
168 | Treatment | - | - | - | - | 2件: 41 41, 299 |
169 | Treatment A | - | - | - | - | 2件: 34 34, 46 |
170 | Treatment Algorithm A | - | - | - | - | 1件: 97 97 |
171 | Treatment Algorithm B | - | - | - | - | 1件: 97 97 |
172 | Treatment Algorithm C | - | - | - | - | 1件: 97 97 |
173 | Treatment as Usual (TAU) | - | - | - | - | 1件: 85 85 |
174 | Treatment B | - | - | - | - | 2件: 34 34, 46 |
175 | Treatment BX1514M | - | - | - | - | 1件: 58 58 |
176 | Treatment C | - | - | - | - | 2件: 34 34, 46 |
177 | Treatment D | - | - | - | - | 1件: 34 34 |
178 | Treatment defined only by active substance | - | - | - | - | 1件: 50 50 |
179 | Treatment I | - | - | - | - | 1件: 46 46 |
180 | Treatment II | - | - | - | - | 1件: 46 46 |
181 | Treatment III | - | - | - | - | 1件: 46 46 |
182 | Treatment of MTX | - | - | - | - | 1件: 46 46 |
183 | Treatment of MTX and HCQ | - | - | - | - | 1件: 46 46 |
184 | Treatment of MTX and TwHF | - | - | - | - | 1件: 46 46 |
185 | Treatment of TCM | - | - | - | - | 1件: 46 46 |
186 | Treatment of TwHF | - | - | - | - | 1件: 46 46 |
187 | Treatment Phase Group 4 | - | - | - | - | 1件: 113 113 |
188 | Treatment systemic therapy (prednisone) | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
189 | Treatment taken | - | - | - | - | 1件: 113 113 |
190 | Treatment vs control bread | - | - | - | - | 1件: 97 97 |
191 | Treatment with Adalimumab | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 |
192 | Treatment with azathioprin | - | - | - | - | 1件: 95 95 |
193 | Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor | 4件: Elexacaftor Elexacaftor, Ivacaftor, Lumacaftor, Tezacaftor | 4件: D09916
D09916
,
D10134
,
D11041
,
D11507
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
194 | Treatment with mycophenolat mofetil | - | - | - | - | 1件: 95 95 |
195 | Treatment with polyethylene glycol (Macrogol 4000) | 1件: Polyethylene glycol Polyethylene glycol | 1件: D03370
D03370
| - | - | 1件: 299 299 |
196 | Treatment with systemic therapy (doxycycline) | 1件: Doxycycline Doxycycline | 2件: D00307
D00307
,
D07876
| - | - | 1件: 162 162 |
197 | Treatment with systemic therapy (methotrexate) | 1件: Methotrexate Methotrexate (Synonym: Trexall) | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 162 162 |
198 | Treatment with systemic therapy (prednisone) | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 |
199 | Treatment with topical superpotent corticosteroid therapy | - | - | - | - | 1件: 162 162 |
200 | Tregalizumab | 1件: Tregalizumab Tregalizumab | - | - | - | 1件: 46 46 |
201 | Trehalose | 1件: Trehalose Trehalose | - | - | - | 3件: 2 2, 6, 113 |
202 | TREMFYA | 1件: Guselkumab Guselkumab (Synonym: Tremfya) | 1件: D10438
D10438
(Name: Tremfya (TN)) | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 37 37, 97 |
203 | TREMFYA® | 1件: Guselkumab Guselkumab (Synonym: Tremfya) | 1件: D10438
D10438
(Name: Tremfya (TN)) | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 2件: 37 37, 97 |
204 | TREOSULFAN | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
(Name: Treosulfan) | - | - | 6件: 13 13, 19, 62, 65, 283, 286 |
205 | Treprosinil Diethanolamine | - | - | - | - | 1件: 86 86 |
206 | Treprostin | - | - | - | - | 1件: 86 86 |
207 | Treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 6件: 51 51, 84, 85, 86, 88, 210 |
208 | Treprostinil dietanolamina | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
209 | Treprostinil diethanolamine | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 2件: 51 51, 86 |
210 | Treprostinil Diolamine | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
211 | Treprostinil Inhalation Powder | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
212 | Treprostinil inhalations | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
213 | Treprostinil Injectable Product | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
214 | Treprostinil Palmitil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
215 | TREPROSTINIL SODIUM | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 3件: 51 51, 86, 88 |
216 | Treprostinil sodium for inhalation | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 85 85 |
217 | Treprostinil Sodium Solution for Inhalation | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
218 | TREPROSTINIL SODIUM, UT-15 | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
219 | Treprostinil, UT-15, LRX-15, 15AU81, BW A15AU, U-62, 840 | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
220 | Treprostinilo | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
221 | Tretinoin | 1件: Tretinoin Tretinoin | 1件: D00094
D00094
(Name: Tretinoin) | 3件: PML PML, RARA, RARB 💬 | 12件: Acute myeloid leukemia Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | 3件: 2 2, 62, 75 |
222 | Tretinoin and Pioglitazone HCL | 2件: Pioglitazone Pioglitazone, Tretinoin | 2件: D00094
D00094
(Name: Tretinoin),
D08378
| 4件: PML PML, PPARG, RARA, RARB 💬 | 21件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 2 2 |
223 | TRETINOINA | 1件: Tretinoin Tretinoin | 1件: D00094
D00094
(Name: Tretinoin) | 3件: PML PML, RARA, RARB 💬 | 12件: Acute myeloid leukemia Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 75 75 |
224 | Trexan | - | - | - | - | 2件: 46 46, 97 |
225 | Trexan inj 25 mg/ml | - | - | - | - | 1件: 97 97 |
226 | Trexan+Salazopyrin+Oxiklorin+prednisolone | 1件: Prednisolone Prednisolone | 1件: D00472
D00472
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 |
227 | Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab | 2件: Infliximab Infliximab, Prednisolone | 2件: D00472
D00472
,
D02598
| 2件: NR3C1 NR3C1, TNF 💬 | 68件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
228 | TYVASO® (treprostinil) inhalation solution, for oral inhalation use | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 85 85 |
229 | Untreated to atorvastatin treatment | 1件: Atorvastatin Atorvastatin | 1件: D07474
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
230 | Usual dopaminergic per os treatment | - | - | - | - | 1件: 6 6 |
231 | UT-15C (treprostinil diethanolamine) | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
232 | UT-15C SR (treprostinil diethanolamine) | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
(Name: Treprostinil) | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
233 | Vancomycin Pre-Treat | 1件: Vancomycin Vancomycin | 1件: D00212
D00212
| - | - | 1件: 97 97 |
234 | Vancomycin Pre-Treatment | 1件: Vancomycin Vancomycin | 1件: D00212
D00212
| - | - | 1件: 97 97 |
235 | Viral load driven treatment interruption | - | - | - | - | 1件: 265 265 |